Marius Lund-Iversen1,2, Helge Scott3,2, Erik H Strøm3, Noah Theiss4, Odd Terje Brustugun5, Bjørn H Grønberg6,7. 1. Department of Pathology, Oslo University Hospital, Oslo, Norway Marius@lund-iversen.com. 2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3. Department of Pathology, Oslo University Hospital, Oslo, Norway. 4. Ventana Medical Systems, Tucson, AZ, U.S.A. 5. Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway. 6. Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 7. The Cancer Clinic, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Abstract
BACKGROUND/AIM: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue. MATERIALS AND METHODS: Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-α with immunohistochemistry. RESULTS:Biopsies from 222 patients were analyzed. Twenty-three percent were ER-α positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-α positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003). CONCLUSION: ER-α is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women. Copyright
RCT Entities:
BACKGROUND/AIM: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue. MATERIALS AND METHODS: Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-α with immunohistochemistry. RESULTS: Biopsies from 222 patients were analyzed. Twenty-three percent were ER-α positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-α positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003). CONCLUSION: ER-α is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women. Copyright
Authors: Hang Li; Jun Che; Mian Jiang; Ming Cui; Guoxing Feng; Jiali Dong; Shuqin Zhang; Lu Lu; Weili Liu; Saijun Fan Journal: Cell Commun Signal Date: 2020-09-17 Impact factor: 5.712
Authors: Antonio Martínez-Ortega; Álvaro Flores-Martinez; Eva Venegas-Moreno; Elena Dios; Diego Del Can; Eloy Rivas; Ariel Kaen; Eugenio Cárdenas Ruiz-Valdepeñas; Elena Fajardo; Florinda Roldán; Natividad González-Rivera; Rosario Oliva; José Ignacio Fernández-Peña; Alfonso Soto-Moreno; David A Cano Journal: J Clin Med Date: 2022-01-05 Impact factor: 4.241
Authors: Patricia A Young; Diana C Márquez-Garbán; Zorawar Singh Noor; Neda Moatamed; David Elashoff; Tristan Grogan; Tahmineh Romero; Hironobu Sasano; Ryoko Saito; Rebecca Rausch; Nalo Hamilton; Steven M Dubinett; Edward B Garon; Richard J Pietras Journal: JTO Clin Res Rep Date: 2021-02-03